Truxima and Dermatomyositis - a phase IV clinical study of FDA data

Summary:

Dermatomyositis is reported as a side effect among people who take Truxima (rituximab-abbs), especially for people who are female, also take Prednisone, and have Polymyositis.

The phase IV clinical study analyzes which people have Dermatomyositis when taking Truxima. It is created by eHealthMe based on reports of 4,063 people who have side effects when taking Truxima from the FDA, and is updated regularly.

What is Truxima?

Truxima has active ingredients of rituximab-abbs. eHealthMe is studying from 4,063 Truxima users. Check the latest studies of Truxima.

What is Dermatomyositis?

Dermatomyositis (inflammation of the skin and underlying muscle tissue, typically occurring as an autoimmune condition or associated with internal cancer) is found to be associated with 263 drugs and 415 conditions by eHealthMe. Check the latest studies of Dermatomyositis.

On Jul, 11, 2026

4,063 people reported to have side effects when taking Truxima.
Among them, 29 people (0.71%) have Dermatomyositis.

Among these 29 people:

What is the gender of people who have Dermatomyositis when taking Truxima? *

female: 100 %
male: 0.0 %

What are other drugs people take besides Truxima? *

What are other side effects people have besides Dermatomyositis? *

Rashes (redness): 4 people, 13.79%
Pain: 4 people, 13.79%
Polymyositis (inflammatory muscle disease that causes weakness of the skeletal muscles): 3 people, 10.34%
Joint Pain: 3 people, 10.34%
Wound: 2 people, 6.90%
Interstitial Lung Disease: 2 people, 6.90%
Pain In Extremity: 2 people, 6.90%
Fever: 2 people, 6.90%
Headache (pain in head): 2 people, 6.90%
Ill-Defined Disorder: 2 people, 6.90%

What are the existing conditions these people have? *

Polymyositis (inflammatory muscle disease that causes weakness of the skeletal muscles): 3 people, 10.34%
Pain: 2 people, 6.90%
Juvenile Rheumatoid Arthritis (joint inflammation in children due to systemic disease): 2 people, 6.90%
Interstitial Lung Disease: 2 people, 6.90%
Idiopathic Pulmonary Fibrosis (chronic lung disease): 2 people, 6.90%
Myopathy (a muscular disease in which the muscle fibres do not function): 1 person, 3.45%
Joint Pain: 1 person, 3.45%

* Approximation only. Some reports may have incomplete information.

Do you take Truxima and have Dermatomyositis?

- Check whether Dermatomyositis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Truxima:

Truxima (4,063 reports)

Dermatomyositis treatments and more:

Dermatomyositis (8,399 reports)

Browse all side effects of Truxima:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Dermatomyositis:

Dermatomyositis (263 drugs)

Browse all the conditions that are associated with Dermatomyositis:

Dermatomyositis (415 conditions)

Related publications that referenced our studies

Kato, M., Oiso, N., Nozaki, Y., Inoue, A., Hosono, Y., Funauchi, M., ... & Kawada, A., "Antitumor necrosis factor alpha inhibitor‐induced dermatomyositis and interstitial lung disease with anti‐PL 12 autoantibody: Signs of antisynthetase syndrome", The Journal of dermatology, 2012 Jan .
Kato, M., Oiso, N., Nozaki, Y., Inoue, A., Hosono, Y., Funauchi, M., ... & Kawada, A., "Antitumor necrosis factor alpha inhibitor‐induced dermatomyositis and interstitial lung disease with anti‐PL 12 autoantibody: Signs of antisynthetase syndrome", The Journal of dermatology, 2012 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on rituximab-abbs (the active ingredients of Truxima) and Truxima (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.